[go: up one dir, main page]

HK1208353A1 - Solid dosage form - Google Patents

Solid dosage form Download PDF

Info

Publication number
HK1208353A1
HK1208353A1 HK15108989.9A HK15108989A HK1208353A1 HK 1208353 A1 HK1208353 A1 HK 1208353A1 HK 15108989 A HK15108989 A HK 15108989A HK 1208353 A1 HK1208353 A1 HK 1208353A1
Authority
HK
Hong Kong
Prior art keywords
dosage form
solid dosage
active material
biologically active
oral cavity
Prior art date
Application number
HK15108989.9A
Other languages
Chinese (zh)
Inventor
Chin Beng Stephen Lim
Vivian Bruce Sunderland
Yip Hang Eddy Lee
Original Assignee
Ix Biopharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2012238330A external-priority patent/AU2012238330B1/en
Application filed by Ix Biopharma Ltd filed Critical Ix Biopharma Ltd
Publication of HK1208353A1 publication Critical patent/HK1208353A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/4045Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4468Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/55131,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/55171,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06Tripeptides
    • A61K38/063Glutathione
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2095Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

There is provided a solid dosage form adapted for the release of a biologically active material in the oral cavity wherein the dosage form comprises at least one biologically active material, and at least one matrix forming agent, wherein the dosage form substantially dissolves in the oral cavity. A method of producing the same and a kit comprising the same are also provided.
HK15108989.9A 2012-10-11 2013-10-11 Solid dosage form HK1208353A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
AU2012238330A AU2012238330B1 (en) 2010-10-26 2012-10-11 Fast Dissolving Solid Dosage Form
AU2012238330 2012-10-11
AU2013200684 2013-02-08
AU2013200682A AU2013200682C1 (en) 2010-10-26 2013-02-08 Fast Dissolving Solid Dosage Form
AU2013200684A AU2013200684B1 (en) 2010-10-26 2013-02-08 Fast Dissolving Solid Dosage Form
AU2013200682 2013-02-08
PCT/IB2013/002594 WO2014057351A1 (en) 2012-10-11 2013-10-11 Solid dosage form

Publications (1)

Publication Number Publication Date
HK1208353A1 true HK1208353A1 (en) 2016-03-04

Family

ID=50478109

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15108989.9A HK1208353A1 (en) 2012-10-11 2013-10-11 Solid dosage form

Country Status (11)

Country Link
EP (1) EP2906201A4 (en)
JP (1) JP2015533155A (en)
KR (1) KR20150063567A (en)
CN (2) CN107669649A (en)
CA (1) CA2886573C (en)
HK (1) HK1208353A1 (en)
IL (2) IL238104B (en)
MY (1) MY191875A (en)
NZ (1) NZ706302A (en)
SG (1) SG11201502425WA (en)
WO (1) WO2014057351A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6217052B2 (en) * 2016-04-21 2017-10-25 邦赫 小牧 Effervescent tablet for oral cleaning
US12427121B2 (en) 2016-05-05 2025-09-30 Aquestive Therapeutics, Inc. Enhanced delivery epinephrine compositions
KR20190005199A (en) 2016-05-05 2019-01-15 어퀘스티브 테라퓨틱스, 아이엔씨. Enhanced delivery fffffrin composition
US12433850B2 (en) 2016-05-05 2025-10-07 Aquestive Therapeutics, Inc. Enhanced delivery epinephrine and prodrug compositions
JP2017193547A (en) * 2017-05-08 2017-10-26 邦赫 小牧 Foaming tablet for oral cleaning
CN111465391A (en) * 2017-09-27 2020-07-28 阿奎斯蒂弗医疗股份有限公司 Compositions of epinephrine and prodrug with enhanced delivery
KR102845228B1 (en) * 2017-09-27 2025-08-14 어퀘스티브 테라퓨틱스, 아이엔씨. Pharmacological compositions having enhanced penetration
IT201800003507A1 (en) * 2018-03-13 2019-09-13 Fulton Medicinali S P A SUBLINGUAL TABLET INCLUDING SILDENAFIL CITRATE
PE20212249A1 (en) * 2019-01-07 2021-11-24 Antecip Bioventures Ii Llc COMBINATION OF DEXTROMETORPHAN AND BUPROPION FOR THE TREATMENT OF DEPRESSION
CN109846841B (en) * 2019-01-18 2021-06-01 西安力邦医药科技有限责任公司 Quick-acting clobazam oral freeze-dried preparation and preparation method thereof
US20220062200A1 (en) * 2019-05-07 2022-03-03 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
US11382873B1 (en) * 2021-01-08 2022-07-12 Vitalis Analgesics LLC Oral administration of ketamine
WO2023076281A1 (en) 2021-10-25 2023-05-04 Aquestive Therapeutics, Inc. Oral and nasal compositions and methods of treatment
WO2025120580A1 (en) * 2023-12-08 2025-06-12 Ix Biopharma Ltd Compositions and methods for initiating a mucosal immune response

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596298B2 (en) * 1998-09-25 2003-07-22 Warner-Lambert Company Fast dissolving orally comsumable films
US6552024B1 (en) * 1999-01-21 2003-04-22 Lavipharm Laboratories Inc. Compositions and methods for mucosal delivery
CA2417736A1 (en) * 2000-07-19 2002-01-24 Lavipharm Laboratories, Inc. Sildenafil citrate solid dispersions having high water solubility
US7118765B2 (en) * 2001-12-17 2006-10-10 Spi Pharma, Inc. Co-processed carbohydrate system as a quick-dissolve matrix for solid dosage forms
WO2004075877A1 (en) * 2003-02-24 2004-09-10 Pharmaceutical Productions, Inc. Transmucosal drug delivery system
WO2007002125A1 (en) * 2005-06-23 2007-01-04 Schering Corporation Rapidly absorbing oral formulations of pde5 inhibitors
WO2009045022A2 (en) * 2007-10-03 2009-04-09 C.L. Pharm Edible film
KR100905027B1 (en) * 2007-10-03 2009-06-30 (주)씨엘팜 Edible Film
DE102008014533A1 (en) * 2008-03-15 2009-09-17 Lts Lohmann Therapie-Systeme Ag Gingival wafer
US8623401B2 (en) * 2008-03-27 2014-01-07 Fenwafe Inc. Wafer formulation
US8715715B2 (en) * 2008-11-03 2014-05-06 Nal Pharmaceuticals Ltd. Dosage form for insertion into the mouth
NZ599594A (en) * 2009-10-30 2014-06-27 Ix Biopharma Ltd Fast dissolving solid dosage form
EP2549988A1 (en) * 2010-03-23 2013-01-30 Apr Applied Pharma Research S.A. Fast dissolving drug delivery systems
FR2967066B1 (en) * 2010-11-04 2013-06-14 Ethypharm Sa SUBLINGUAL USE OF NON-COMPRESSED MICROGRANULES
JP5841433B2 (en) * 2012-01-11 2016-01-13 日東電工株式会社 Intraoral film-form base and preparation
HK1206558A1 (en) * 2013-03-15 2016-01-15 Aerpio Therapeutics Inc Compositions, formulations and methods for treating ocular diseases

Also Published As

Publication number Publication date
SG11201502425WA (en) 2015-05-28
IL238104B (en) 2020-03-31
MY191875A (en) 2022-07-18
JP2015533155A (en) 2015-11-19
KR20150063567A (en) 2015-06-09
WO2014057351A1 (en) 2014-04-17
CN104812378B (en) 2017-12-01
IL238104A0 (en) 2015-05-31
EP2906201A1 (en) 2015-08-19
IL273076A (en) 2020-04-30
CN104812378A (en) 2015-07-29
CA2886573A1 (en) 2014-04-17
CA2886573C (en) 2019-04-02
CN107669649A (en) 2018-02-09
NZ706302A (en) 2017-07-28
EP2906201A4 (en) 2016-10-19

Similar Documents

Publication Publication Date Title
HK1208353A1 (en) Solid dosage form
MY150626A (en) Fast dissolving solid dosage form
EP2279227A4 (en) Anionic latex as a carrier for active ingredients and methods for making and using the same
MX2015017036A (en) Method for producing renal precursor cells, and drug containing renal precursor cells.
ZA201001015B (en) (Carboxylalkylene-phenyl)-phenyl-oxalamides, method for the production thereof, and use of same as a medicament
MX2013008850A (en) Compositions and methods for treating cardiovascular diseases.
IL204556A0 (en) (cyclopropyl-phenyl)-phenyl-oxalamides, method for the production thereof, and use of same as a medicament
JO3052B1 (en) Dividable galenical form allowing modified release of the active ingredient
WO2012080833A3 (en) Controlled release dosage forms
WO2012100097A3 (en) Topical minocycline compositions and methods of using the same
WO2010117738A3 (en) Solid state forms of sitagliptin salts
MY162411A (en) Crystalline forms of a macrolide, and uses therefor
EP2844185B8 (en) Method for producing dentures and articulator for carrying out the method
GEP20146078B (en) Processes for pharmaceutically active agent manufacture
PH12014502834B1 (en) Pharmaceutical form for extended release of active substances
WO2009149058A8 (en) Modified release niacin formulations
WO2012106016A3 (en) Oral care compositions
WO2010148314A3 (en) Preparation of esomeprazole and its pharmaceutically acceptable salts
EP2730585A4 (en) Protein-polypeptide complex with a specific effect on skin tissue, method for producing said complex and pharmaceutical composition on the basis thereof
MX349563B (en) Pharmaceutical formulation of nanonised fenofibrate.
WO2012127495A3 (en) Pharmaceutical composition and process for preparation thereof
WO2011062936A3 (en) Self-assembled toroidal-spiral particles and manufacture and uses thereof
WO2010063483A3 (en) Active ingredient-peptide construct for extracellular enrichment
MY197131A (en) Fast dissolving solid dosage form
WO2012146736A8 (en) Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium salts in the treatment of cardiovascular disease